// App-Quantinova.ai

: Estimating long term effect of siponimod on disability progression versus virtual placebo in SPMS using RPSFT model EXPAND data up to 7 years

Researchers

Presenter

  • Bruce Cree

Principal Investigators

  • Nicolas Rouyrre

  • Robert Fox

  • Patrick Vermersch

  • Gavin Giovannoni

  • Amit Bar-Or

  • Ralf Gold

  • Jeff Maca

  • Daniela Piani Meier

  • Karlsson Goeril

  • Ludwig Kappos

Medical Centers

  • Novartis Pharma GmbH

  • Mellen Center for Treatment and Research in Multiple Sclerosis, Cleveland Clinic

  • Univ. Lille, Inserm U LilNCog, FHU Precise

  • Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK

  • University of Pennsylvania, PA.

  • Department for Neurology, St. Josef-Hospital, Ruhr University, Bochum, Germany

  • Novartis Pharmaceuticals Corporation, New York, NY

  • Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland

Locations

  • France

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Siponimod

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved